Skip to main content
. 2019 Sep 30;3(19):2790–2799. doi: 10.1182/bloodadvances.2019000175

Table 2.

Multivariate prognostic models for OS and EFS in patients with DLBCL

Outcome Model Variable Hazard ratio 95% CI (lower) 95% CI (upper) P Log-rank P
OS wp-score wp-score (high)* Infinite 0.000 Infinite ND .001
Age 0.98 0.29 1.02 .29
Sex (female) 2.49 0.26 12.29 .26
EFS wp-score wp-score (high) 9.17 2.01 41.89 .004 .002
Age 0.98 0.94 1.02 .29
Sex (female) 2.23 0.59 8.41 .24
wp-score + LDH wp-score (high) 10.85 2.24 52.64 .003 .001
LDH (elevated) 5.99 1.47 24.49 .01
Age 0.96 0.92 1.00 .05
Sex (female) 1.23 0.29 5.12 .78
wp-score + IPI wp-score (high) 14.28 1.54 132.84 .02 <.001
IPI (high) 23.44 3.12 175.87 .002
Age 0.94 0.88 1.01 .09
Sex (female) 11.13 0.97 128.17 .05
wp-score + GCB vs ABC wp-score (high) 20.08 1.37 293.60 .03 .02
Cell of origin 4.47 0.78 25.73 .09
Age 0.93 0.86 1.00 .05
Sex (female) 4.27 0.50 36.92 .19
wp-score + stage wp-score (high) 6.55 1.28 33.46 .02 .03
Stage (advanced) 3.99 0.83 19.24 .08
Age 0.98 0.93 1.04 .52
Sex (female) 2.37 0.50 11.26 .28

ND, not defined.

*

All patients in the high wp-score group are alive at the end of the follow-up period. Thus, the β estimate is infinite for OS analysis.